Lupin shares rise 2% on launching heart drug in Canada

[ad_1] Business News, Strategy, Finance and Corporate Insight  Fortune India [ad_2] Source link

US FDA flags ‘significant violations’ of CGMP norms at Gujarat-based Intas Pharma

[ad_1] The US federal health agency Food and Drug Administration (USFDA) has issued a warning letter to Gujarat-based Intas Pharmaceuticals for “significant violations” in following current good manufacturing practice (CGMP)…